Characterization of a re‐engineered, mesothelin‐targeted<i>Pseudomonas</i>exotoxin fusion protein for lung cancer therapy
Frieder Bauss(Roche Pharma AG (Germany)), Gerhard Niederfellner(Roche (Switzerland)), Frank Herting(Roche Pharma AG (Germany)), Klaus Bosslet(University of Giessen), Marc Pompiati, Wilma Lau, Birgit Bossenmaier(Baum Consult), Ulrich Brinkmann(Roche (Switzerland)), Jan Olaf Stracke(University of East Anglia), Ira Pastan(National Institutes of Health), Roland F. Staack(Roche Pharma AG (Germany)), Friederike Hesse(University of Cambridge), Rita da Silva Mateus Seidl(Roche Pharma AG (Germany)), Ben‐Fillippo Krippendorff(Roche (Switzerland)), Gwendlyn Kollmorgen(Roche Pharma AG (Germany)), Christian Schantz, Sabine Imhof-Jung, Martin Lechmann(Roche (Switzerland)), Masanori Onda(National Cancer Institute), Matthias Festag(Roche (Switzerland))
Cited by 56
Related Papers
Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum
|JAMA Neurology|2021|627
Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer’s continuum when only subtle changes in Aβ pathology are detected
|EMBO Molecular Medicine|2020|411
α-Galactosidase A deficient mice: A model of Fabry disease
|Proceedings of the National Academy of Sciences|1997|370
High incidence of amplification of the epidermal growth factor receptor gene in human squamous carcinoma cell lines.
|PubMed|1986|368
Matrix metalloproteinases in arthritic disease.
|Arthritis Research|2002|306